LSW Stock Overview
A medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Tissue Regenix Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.69 |
| 52 Week High | UK£0.88 |
| 52 Week Low | UK£0.57 |
| Beta | 1.61 |
| 11 Month Change | 13.22% |
| 3 Month Change | 1.48% |
| 1 Year Change | 10.48% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 37.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LSW | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 12.3% | 0.8% | -2.2% |
| 1Y | 10.5% | -14.4% | 13.3% |
Return vs Industry: LSW exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: LSW underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| LSW volatility | |
|---|---|
| LSW Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LSW's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LSW's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 82 | Danny Lee | www.tissueregenix.com |
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth.
Tissue Regenix Group plc Fundamentals Summary
| LSW fundamental statistics | |
|---|---|
| Market cap | €51.32m |
| Earnings (TTM) | -€1.01m |
| Revenue (TTM) | €29.23m |
1.8x
P/S Ratio-50.7x
P/E RatioIs LSW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LSW income statement (TTM) | |
|---|---|
| Revenue | US$31.80m |
| Cost of Revenue | US$16.06m |
| Gross Profit | US$15.73m |
| Other Expenses | US$16.84m |
| Earnings | -US$1.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 49.48% |
| Net Profit Margin | -3.46% |
| Debt/Equity Ratio | 34.9% |
How did LSW perform over the long term?
See historical performance and comparison